GTX-102 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman
Phase 3 · Angelman Syndrome |
RARE Ultragenyx Pharmaceutical In | GTX-102 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|